Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Verapamil
Drug ID BADD_D02348
Description Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications.[L8791] Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.[A188435]
Indications and Usage For the treatment of hypertension, angina, and cluster headache prophylaxis.
Marketing Status Prescription; Discontinued
ATC Code C08DA01
DrugBank ID DB00661
KEGG ID D02356
MeSH ID D014700
PubChem ID 2520
TTD Drug ID D0R0FE
NDC Product Code 70966-0029
Synonyms Verapamil | Iproveratril | Cordilox | Dexverapamil | Verapamil Hydrochloride | Hydrochloride, Verapamil | Finoptin | Izoptin | Isoptine | Isoptin | Lekoptin | Calan | Falicard
Chemical Information
Molecular Formula C27H38N2O4
CAS Registry Number 52-53-9
SMILES CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.000112%
Loss of consciousness17.02.04.004--Not Available
Macular oedema06.04.06.005--Not Available
Macule23.03.03.037--Not Available
Malaise08.01.01.0030.000646%
Menstrual disorder21.01.01.004--Not Available
Metabolic acidosis14.01.01.0030.000861%Not Available
Micturition urgency20.02.02.006--
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.005--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nodal rhythm02.03.02.0060.001292%Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oligomenorrhoea21.01.02.004; 05.05.01.011--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Paralysis17.01.04.004--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngitis11.01.13.003; 07.05.07.004; 22.07.03.004--
Pollakiuria20.02.02.007--
Presyncope17.02.05.009; 24.06.02.010; 02.01.02.0070.000646%
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.0030.001723%
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages